Prescription costs keep spiraling higher …
(Bob Herman, AXIOS) Humira, the heavily touted anti-inflammatory drug, netted $13.6 billion in gross U.S. sales last year — the most of any brand-name prescription drug.
[According to reports, Humira costs approximately $4,370 per patient per month. The median U.S. household income is $4,919 per month. Editor]
In all, the 20 top-selling drugs combined generated more than $98 billion in gross U.S. sales in 2016.
The growth in pharmaceutical spending continues to be well above inflation, putting many people in a bind when they pick up their medicine at the pharmacy.
QuintilesIMS, a pharmaceutical research firm, collected the data in an annual report.
Peak global revenue for Humira is projected to hit $20 billion before so-called “biosimilar” versions hit the market in 2022 and eat into sales. READ THE FULL STORY AT AXIOS.COM.